Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 925 results for "astrazeneca"

FDA Gives Thumbs Up to Ovarian Cancer Drug Lynparza (Olaparib)
Tech Times

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA ...

Summary On Friday, AstraZeneca announced accelerated FDA Approval for Lynparza. This comes a day after the EU approved Lynparza (olaparib). I reiterate my bull thesis on AstraZeneca. The company projects Lynparza to be a $2 billion-a-year seller, ... Seeking Alpha, 15 hours ago

318 images for astrazeneca

Press TV, 1 day ago
Yahoo! News Australia, 1 day ago
CTV News, 2 days ago
International Business Times UK, 4 days ago
Yahoo! News, 2 days ago
American Banking News, 4 days ago
Reuters UK, 1 day ago
Reuters UK, 1 day ago
Bidness Etc, 3 days ago
Reuters, 2 days ago

AstraZeneca's Lynparza gains FDA approval

The US Food and Drug Administration has granted accelerated approved for Anglo-Swedish drug major AstraZeneca's (LSE: AZN) Lynparza (olaparib) capsules as monotherapy for the treatment of patients with deleterious or suspected deleterious germline ...
 Pharma Letter3 hours ago AstraZeneca : LYNPARZA approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations  4 Traders2 days ago LYNPARZA APPROVED BY THE US FDA  MoneyAM2 days ago FDA Approves AstraZeneca's Lynparza To Treat Advanced Ovarian Cancer  RTTNews.com2 days ago
Yahoo! UK and Ireland

3 Top Blue-Chip Stocks For Next Year: AstraZeneca plc, Burberry Group plc And Tesco PLC

These 3 stocks could deliver better-than-expected performances next year: AstraZeneca plc (LON: AZN), Burberry Group plc (LON: BRBY) and Tesco PLC
 Yahoo! UK and Ireland4 hours ago

BioCity Announces New Investment Fund with AstraZeneca

BioCity, the Bioscience incubation specialist with locations in the United Kingdom—East Midlands (BioCity and Medicity in Nottingham), the North West (BioHub at Alderley Park, and Scotland (BioCity Scotland at Newhouse)—has announced a new ...
 PharmTech.com7 hours ago

Astrazeneca delisting: Test case for Sebi's rule on 10% cap for FIIs

Astrazeneca Pharma's delisting could be delayed further with some aggrieved shareholders moving the SAT claiming the process was rigged. The post Astrazeneca delisting: Test case for Sebi’s rule on 10% cap for FIIs appeared first on Firstpost .
 First Post.com23 hours ago AstraZeneca: Test case for Sebi's rule on 10% cap for FIIs  Money Control3 weeks ago
Reuters UK

New Pfizer bid unlikely says AstraZeneca CEO

s Editor "I consider it unlikely that Pfizer (NYSE:PFE) will return with a bid," reports Swedish business daily Dagens Industri quoting AstraZeneca (NYSE:AZN) CEO Pascal Soriot. "I can't say it will never happen, but the probability that Pfizer ...
 Seeking Alpha1 day ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI  4 Traders1 day ago New Pfizer bid unlikely, says AstraZeneca CEO hours ago
Pharmaceutical Business Review


Regulatory Story AstraZeneca PLC - AZN Released 17:40 19-Dec-2014 RNS Number : 3820A AstraZeneca PLC 19 December 2014  LYNPARZA approved by the US FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN PATIENTS WITH GERMLINE ...
 London Stock Exchange2 days ago Update: AstraZeneca Wins EU Approval For Lynparza  Seeking Alpha3 days ago Olaparib Approved in Europe for BRCA Ovarian Cancer  General Medicine eJournal3 days ago AstraZeneca cancer drug cleared in Europe  Seeking Alpha4 days ago

AstraZeneca (AZN) Showing Support Near $68.60's patented algorithms have selected a trade on AstraZeneca Plc ("AZN) that returns 7.76% in 121 days for an annualized return rate of 23%. This diagonal spread pairs a ...
 Individual.com4 days ago AstraZeneca (AZN) Showing Bearish Technicals With Resistance At $73.94  Individual.com6 days ago

FDA clears Myriad's companion diagnostic test for Lynparza

News Editor The FDA approves Myriad Genetics' (MYGN +1.4%) BRACAnalysis CDx as the companion diagnostic test to AstraZeneca's (AZN -0.9%) Lynparza (olaparib). BRACAnalysis CDx identifies BRCA1 and BRCA2 mutations in a
 Seeking Alpha2 days ago FDA approves Myriad's BRACAnalysis CDx for use with ovarian cancer drug  News-Medical.Net4 hours ago Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM) (olaparib) in Ovarian Cancer Patients  4 Traders2 days ago

Potential AstraZeneca (AZN) Trade Targets 4.49% Return

WednesdayaEUR(TM)s trading in AstraZeneca Plc ("AZN) gives options traders an opportunity for a 17.65% return. By selling the Apr. '15 $70.00 call and buying the Jan. '16 call at the $55.00 level for ...
 Individual.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less